Leukaemia inhibitory factor is associated with treatment resistance in oesophageal adenocarcinoma

Oesophageal cancer is an aggressive disease with a poor 5 year survival rate of <20% of diagnosed patients. Unfortunately, only 20-30% Oesophageal Adenocarinoma (OAC) patients show a beneficial response to neoadjuvant therapy (neoCT). Inflammation influences OAC given the increased risk of cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Buckley, Amy M., Lynam-Lennon, Niamh, Kennedy, Susan A., Dunne, Margaret R., Aird, John J., Foley, Emma K., Clarke, Niamh, Ravi, Narayanasamy, O’Toole, Dermot, Reynolds, John V., Kennedy, Breandán N., O’Sullivan, Jacintha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154751/
https://www.ncbi.nlm.nih.gov/pubmed/30263091
http://dx.doi.org/10.18632/oncotarget.25950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154751/
https://www.ncbi.nlm.nih.gov/pubmed/30263091
http://dx.doi.org/10.18632/oncotarget.25950

Ejemplares similares